Results of a pivotal phase III trial that led to approval of pemetrexed as the first maintenance therapy in locally advanced or metastatic nonsquamous non-small cell lung cancer are being published online Sept. 19 by the Lancet. Pemetrexed (Alimta) maintenance improved median overall survival by 2.8 months and median progression-free survival by 1.7 months in the placebo-controlled, 663-patient trial, according to the paper by lead author Dr. Tudor Ciuleanu of the Cancer Institute Ion Chiricuta,...